{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-078207","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2024-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.959167+00:00","generated_at":"2026-05-31T23:04:43.507668+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Outlook Therapeutics gets UK MHRA approval for LYTENAVA (bevacizumab gamma) for wet AMD","bullets":["UK MHRA granted Marketing Authorization for LYTENAVA (bevacizumab gamma) to treat wet age-related macular degeneration.","LYTENAVA is the first and only authorized ophthalmic bevacizumab formulation for wet AMD in the EU and UK.","Approval leveraged EMA positive opinion under the new International Recognition Procedure.","This regulatory milestone supports Outlook's commercial strategy in the UK market."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-078207","json":"https://secwatch.observer/filing/0001104659-24-078207.json","markdown":"https://secwatch.observer/filing/0001104659-24-078207.md","text":"https://secwatch.observer/filing/0001104659-24-078207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465924078207/0001104659-24-078207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465924078207/tm2418995d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:04:43.507668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}